Bristol-Myers Squibb Company (BMY)
US FDA allows use of Bristol's cell therapy for rare blood cancer
The U.S. Food and Drug Administration has allowed expanded use of Bristol Myers Squibb's cell therapy, Breyanzi, for an aggressive and rare type of blood cancer that affects the body's disease fighting cells, the company said on Thursday.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bristol Myers Squibb Shares Cross 6% Yield Mark
In trading on Wednesday, shares of Bristol Myers Squibb were yielding above the 6% mark based on its quarterly dividend (annualized to $2.4), with the stock changing hands as low as $39.94 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.
This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A
Targeted radiopharmaceuticals has caught the eye of big pharma. The therapy delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule.
This Unpopular Dividend Stock Is a Buy
High-yield dividend stocks, on balance, are incredible value creators for long-term investors. Bristol Myers Squibb's yield has swelled to 5.6% this year, creating a compelling opportunity for patient investors.
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
Top Wall Street Strategist Sees 500 Point S&P 500 Drop – Buy 6 Passive Income Dividend Stocks Now
Want to Retire Early?
1 Stock I Wouldn't Touch With a 10-Foot Pole
Bristol Myers Squibb had a punishing first quarter. It's undergoing a new cost-cutting campaign as a result.
3 Bargain Stocks to Buy Now: May 2024
Since the bull market began in November 2022, growth stocks have outperformed value by a significant margin. Nevertheless, value S&P 500 sectors like financials and utilities have led over the past two months as the market has broadened out.
Insider Trading is Good News for These Stocks
Insiders are buying these hot stocks that have ample upside for investors. The list includes pharma, entertainment, and financial stocks and Berkshire buys.
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult patients with relapsed or refractory follicular lymphoma.
